Hysterectomy Malpractice Lawsuit Filed Against Virginia Doctor

A Virginia doctor faces a medical malpractice lawsuit for perforating a woman’s large intestine and puncturing her bladder during a hysterectomy. 

Miriam Cenedese filed the complaint last month against the Hampton VA Medical Center in federal court in Virginia, alleging that Dr. David Ostman was grossly negligent for using his hands to tear open a hole in a her large intestine and bladder. According to a report by The Virginia-Pilot, the lawsuit came after the U.S. Department of Veterans Affairs rejected an administrative claim for compensation by Cenedese.

According to the complaint, Cenedese went to Dr. Ostman for a hysterectomy in 2008, but he allegedly botched the procedure by deciding to conduct a temporary ileostomy with his hands instead of a cutting instrument. An ileostomy is a surgical hole in the abdomen that allows body waste to be voided into a pouch. The lawsuit claims Dr. Ostman ripped open holes in Cenedese intestine and bladder with his hands because he failed to identify the correct parts of her anatomy.

Did You Know?

Change Healthcare Data Breach Impacts Millions of Customers

A massive Change Healthcare data breach exposed the names, social security numbers, medical and personal information of potentially 100 million Americans, which have now been released on the dark web. Lawsuits are being pursued to obtain financial compensation.

Learn More

This is not the first time Dr. Ostman has faced legal trouble surrounding the care provided to patients.

In 2004, the Virginia Board of Medicine issued a reprimand against Dr. Ostman for writing hundreds of prescriptions for a “Lotion” that was designed to boost the sex drive of women. He used a personal website to take orders for the topical lotion, which is loaded with testosterone and not approved for use as a female sex drive enhancer by the FDA.

The board also determined that Dr. Ostman ran a so-called “pill mill” from his office; handing out thousands of doses of Vicodin, Xanax, Valium and appetite suppressant pills without a pharmacists’ license. The board ruled that he posed a danger to the health and welfare of his patients, but his license was restored to unrestricted status in 2005.

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Generic Depo-Provera Manufacturers Call for Birth Control Shot MDL to Be Created in NY, Not California
Generic Depo-Provera Manufacturers Call for Birth Control Shot MDL to Be Created in NY, Not California (Posted 2 days ago)

A growing number of lawsuits against generic Depo-Provera manufacturers have been filed throughout the federal court system, each alleging that women were not adequately warned about the risk of meningioma brain tumors from the birth control shot.

Oxbryta Class Action Lawsuit Filed by Former Users of Sickle Cell Disease Drug Recalled in 2024
Oxbryta Class Action Lawsuit Filed by Former Users of Sickle Cell Disease Drug Recalled in 2024 (Posted 3 days ago)

Former users of the recalled sickle cell disease drug Oxbryta have filed a class action lawsuit, claiming the manufacturer failed to warn consumers about risks associated with the medication, which can result in stroke and death.

Group of 20 Uber Driver Sexual Assault Lawsuits Will Be Prepared for Bellwether Trials in Dec. 2025
Group of 20 Uber Driver Sexual Assault Lawsuits Will Be Prepared for Bellwether Trials in Dec. 2025 (Posted 3 days ago)

Plaintiffs and defendants have each been directed to select 10 Uber driver sexual assault lawsuits to serve as potential bellwether trials by February 14, 2025, which will then go through case-specific discovery to prepare for early test trials.